financetom
Business
financetom
/
Business
/
Why Is Diginex Stock Soaring Monday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Diginex Stock Soaring Monday?
Nov 24, 2025 3:55 AM

Diginex Limited ( DGNX ) stock jumped Monday after the sustainability tech firm moved to acquire The Remedy Project, a deal that positions the company at the center of tightening global human-rights rules.

The planned acquisition would merge Diginex's ( DGNX ) AI-driven compliance tools with Remedy's on-the-ground grievance and remediation systems, giving enterprises a unified platform to meet fast-approaching due diligence mandates and escalating demand for credible, worker-centered solutions.

The combined solution will enable enterprises to move beyond risk identification to deliver effective, scalable, and victim-centered remedies in situations where labor rights violations occur.

Also Read: Diginex Bets On Human Rights Tech Boom With Remedy Project MOU

The acquisition comes at a pivotal moment for the transparency and remediation sector.

New mandatory human rights and environmental due diligence laws– such as Corporate Sustainability Due Diligence Directive (CSDDD or CS3D) – explicitly require companies to establish effective grievance mechanisms and provide or enable Remedy when adverse impacts occur.

According to industry analysts, the global market for supply chain sustainability and due diligence software is experiencing growth, with Verdantix forecasting the supply chain sustainability software segment alone to exceed $7 billion by 2029 (up from $1.7 billion in 2023) at a 29% CAGR, primarily driven by regulatory pressure and demand for robust remediation capabilities.

Archana Kotecha will join the Diginex ( DGNX ) Executive Team and focus on remedy innovation and global relationships with corporations and governments worldwide. The acquisition is expected to close within the next 45 days.

Price Action: DGNX stock was trading higher by 11.55% to $13.52  at last check Monday.

Read Next:

This Warren Buffett-Backed Japanese Giant Sees Key Rankings Slip — What Comes Next?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Sep 13, 2024
11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Sep 13, 2024
11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...
Copyright 2023-2026 - www.financetom.com All Rights Reserved